Company Information

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE4025.35184.6 (+4.81 %)
PREV CLOSE ( ) 3840.75
OPEN PRICE ( ) 3855.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 29373
TODAY'S LOW / HIGH ( )3840.75 4040.00
52 WK LOW / HIGH ( )3050.15 4072.35
NSE4016.35172.55 (+4.49 %)
PREV CLOSE( ) 3843.80
OPEN PRICE ( ) 3850.00
BID PRICE (QTY) 4016.35 (2062)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1155173
TODAY'S LOW / HIGH( ) 3836.05 4039.00
52 WK LOW / HIGH ( )3051 4074.4
ChairmanRamesh BV Nimmagadda
Managing DirectorMurali K Divi
Company SecretarySatish Choudhury
Executive DirectorN V Ramana
Non Executive Independent DirectorG Suresh Kumar
R Ranga Rao
KVK Seshavataram
S Ganapaty
Sunaina Singh
K V Chowdary
Whole Time DirectorKiran S Divi
Whole Time Director - CommercialNilima Prasad Divi
Incorporation Year : 12-10 1990

Registered Office :

Address : 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli Hyderabad,
Telangana-500032 .

Phone : 040 66966300

Email :  mail@divislabs.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.